People · Operator
Named in public records as an officer, director or promoter · active 2011–2017 · Biotech / Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Swift Biosciences, Inc. | — | Biotech / Pharma | Series A | $31.5M | $134.0M | 2013 |
| RedPath Integrated Pathology, Inc. | — | Biotechnology | Seed | $2.8M | $27.2M | 2011 |
Peter Kleinhenz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Kleinhenz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian Murphy | 1 | 15 |
| Mark Lewis | 1 | 15 |
| Jack Ball | 1 | 10 |
| Dan Watkins | 1 | 8 |
| Dennis Smith | 1 | 6 |
| Linda Tufts | 1 | 5 |
| Dan Kidle | 1 | 4 |
| Walter Young | 1 | 3 |
| Jack Davis | 1 | 3 |
| Nathan Wood | 1 | 3 |
| Jack Ball, Jr. | 1 | 2 |
| Jack David | 1 | 1 |
| Vladimir Makarov | 1 | 1 |
| David Olson | 1 | 1 |
| Tim Harkins | 1 | 1 |
| Eric Halverson | 1 | 1 |
| Timothy Harkins, PhD | 1 | 1 |
| Mark Myslinski | 1 | 1 |
| Craig S Heryford | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.